Skip to main content

Table 2 Baseline demographic and disease characteristics of patients with PsA stratified by prior anti-TNF therapy

From: Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy

  Patients with PsA (N = 442)
    Prior TNF antagonist(s) Reason for discontinuation of prior TNF antagonista
  No prior ETN/IFX Prior ETN and/or IFX IFX only ETN only IFX and ETN Lack of response Loss of response Intolerance
Characteristic (n = 376) (n = 66) (n = 18) (n = 34) (n = 14) (n = 14) (n = 29) (n = 9)
Male (%) 50 47 61 41 43 50 45 44
Age (years; mean ± SD) 48 ± 11 47 ± 12 44 ± 12 47 ± 13 50 ± 8 43 ± 10 48 ± 13 51 ± 11
PsA duration (years; mean ± SD) 10 ± 8 12 ± 8 13 ± 7 9 ± 8 17 ± 8 7 ± 5 14 ± 7 14 ± 11
Psoriasis (%)b 83 80 78 79 86 79 79 78
Nail dystrophy (%)c 59 55 72 41 64 43 62 11
Concomitant DMARDs (%) 71 52 72 35 64 29 59 44
Concomitant glucocorticoids (%) 26 44 44 41 50 36 41 44
C-reactive protein (mg/dl)d 0.9 1.3 0.8 1.5 1.1 0.8 1.6 1.4
  0.4, 2.2 0.3, 2.8 0.1 to 8.4e 0.1 to 7.0e 0.5 to 4.7e 0.1 to 7.0e 0.1 to 8.4e 0.2 to 3.4e
  1. aNo additional reason except for "other." bPatients with PGA other than "Clear." cPatients with NAPSI score ≥ 1. dReference value, 0.4 mg/dl; values listed are median and quartile 1, quartile 3 because of skewed distribution. eRanges presented are minimum to maximum because of small numbers of patients per group. DMARDs, disease-modifying antirheumatic drug; ETN, etanercept; IFX, infliximab; NAPSI, nail psoriasis severity index; NSAID, nonsteroidal antiinflammatory drug; PGA, Physician's Global Assessment of psoriasis; PsA, psoriatic arthritis; TNF, tumor necrosis factor.